Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
iSpecimen operates a technology-enabled marketplace connecting life science researchers with biospecimen providers (hospitals, laboratories, biobanks) for clinical research. The company faces severe financial distress with negative operating cash flow, declining revenues, and a current ratio of 0.63 indicating potential liquidity crisis. The stock has collapsed 82% over the past year amid operational challenges and capital constraints.
iSpecimen generates revenue by charging life science companies (pharmaceutical, biotech, diagnostics) transaction fees when they procure human biospecimens (blood, tissue, urine samples) through its digital marketplace. The platform aggregates supply from hospitals and biobanks, providing researchers access to diverse patient populations and rare disease samples. Gross margin of 43% suggests moderate pricing power, but the company lacks scale economies - operating margin of -137% indicates fixed platform costs far exceed current transaction volumes. The business model requires critical mass of both specimen suppliers and research buyers to achieve unit economics.
New pharmaceutical or biotech partnership announcements expanding buyer network
Quarterly transaction volume growth and average order value trends
Cash runway updates and financing announcements given liquidity constraints
Regulatory developments affecting biospecimen procurement and patient consent requirements
Competitor marketplace activity or consolidation in fragmented biospecimen industry
Network effects have failed to materialize - the marketplace requires simultaneous scaling of specimen suppliers and research buyers, creating a chicken-and-egg problem that the company has not solved after years of operation
Regulatory fragmentation across states and countries regarding biospecimen collection, patient consent, and data privacy creates compliance complexity that limits marketplace scalability
Large pharmaceutical companies may develop direct relationships with biobanks or build internal procurement capabilities, disintermediating the marketplace model
Established clinical research organizations (CROs) and contract research providers offer biospecimen procurement as part of integrated service packages, bundling advantages iSpecimen cannot match
Hospital systems and academic medical centers increasingly commercialize their own biobanks directly, bypassing third-party marketplaces
Well-capitalized competitors or new entrants could subsidize marketplace growth to achieve critical mass faster than iSpecimen's constrained resources allow
Immediate liquidity crisis - current ratio of 0.63 and negative operating cash flow indicate the company may struggle to meet short-term obligations without additional financing
Equity dilution risk - any capital raise at current depressed valuations would severely dilute existing shareholders, potentially triggering reverse stock split to maintain exchange listing
Going concern risk - auditors may issue going concern warnings if cash runway falls below 12 months without credible financing plan
moderate - Pharmaceutical and biotech R&D spending exhibits some cyclical sensitivity but remains more resilient than discretionary sectors. During economic downturns, smaller biotech firms may reduce clinical trial activity and biospecimen procurement, while large pharmaceutical companies maintain research budgets. Venture capital funding cycles for biotech significantly impact demand from emerging life science companies. The company's distressed financial position makes it vulnerable to any demand softness.
Rising interest rates negatively impact iSpecimen through multiple channels: (1) biotech customer funding becomes scarcer as venture capital contracts, reducing research budgets and specimen procurement; (2) the company's ability to raise growth capital deteriorates as investors demand profitability over growth; (3) higher discount rates compress valuation multiples for unprofitable growth companies. With negative cash flow, the company requires external financing, making capital market conditions critical.
High exposure to credit market conditions. The company's survival depends on access to equity or debt financing given negative operating cash flow and current ratio of 0.63. Tightening credit conditions or risk-off sentiment in biotech equity markets could prevent necessary capital raises. Customer credit risk is moderate - pharmaceutical companies are creditworthy, but smaller biotech customers may face payment delays during funding gaps.
Highly speculative momentum traders and distressed/turnaround investors willing to accept binary outcomes. The 82% one-year decline and severe financial distress eliminate traditional growth or value investors. Only suitable for investors with high risk tolerance expecting either restructuring/acquisition or complete loss. Institutional ownership likely minimal given market cap and liquidity constraints.
high - Stock exhibits extreme volatility with 48% decline in just three months. Micro-cap status, low liquidity, and binary financing outcomes create massive price swings on any news. Implied volatility likely exceeds 100% if options traded. Beta meaningless given idiosyncratic distress factors dominating returns.
